Serum Concentration of Intercellular Adhesion Molecule-1 (ICAM-1) in Patients with Hepatocellular Carcinoma (HCC) with Low AFP

Korean J Hepatol > Volume 4(4); 1998 > Article

The Korean Journal of Hepatology 1998;4(4): 346-357.

저 AFP 간세포암 환자에서 혈중 sICAM-1의 간세포암 표지자로서의 의의 (Serum Concentration of Intercellular Adhesion Molecule-1 (ICAM-1) in Patients with Hepatocellular Carcinoma (HCC) with Low AFP )

Serum Concentration of Intercellular Adhesion Molecule-1 (ICAM-1) in Patients with Hepatocellular Carcinoma (HCC) with Low AFP

Hyun Ju Park, Joung Il Lee, Seok Ho Dong, Hyo Jong Kim, Byoung Ho Kim, Young Woon Chang and Rin Chang

Department of Internal Medicine, KyungHee University School of Medicine

ABSTRACT

Background/Aims
: In HCC with low AFP. we have to use repeated imaging study to evaluate residual viable rumor or recurrence after TACE ( transarterial chemoembolization). We performed the study to know that sICAM- 1 in HCC can be a tumor marker of diagnosis and has cor relation with tumor size or clinical staging. The results were compared with PIVKA- , an another tumor marker of HCC. Met hods : Previously untreat ed 39 pat ients with HCC were evaluated. Serum sICAM- 1, AFP and PIVKA- II were measured by EIA, immunoradiometric assay and EIA, respectively. Tumor size were meas ured by abdominal CT and angiogr aphy. Results : Range of sICAM- 1 levels with HCC patients were 189.0 to 983.6 ng/ mL, and mean value was 668.3+- 254.4 ng/ mL. Thirty four of the 39 patients (87.2%) with HCC showed sICAM- 1 levels higher than 306.4 ng/ mL (mean of 131 healt hy controls + 2SD level). Range of PIVKA-Ⅱ level with HCC patients were 25.3 to 2,779.3mAU/nL, and mean value was 1,340.1+-1,091.1mAU/mL. seven of the 39 patients(94.9%) with HCC showde PIVKA-Ⅱlevels higher than 40mAU/mL. Range of AFP levels with HCC patients were 4.2 to 57,520ng/mL, and mean value was 4,215.6+-10,807.2ng/mL. 10 patients (26%) showed AFP lower than 20ng/mL, and 17 patients(44%) were AFP lower than 100ng/mL. All of the 17 patients with αFP lower than 100ng/mL had s ICAM- 1 levels more than reference range (mean of 131 healt hy cont r ols + 2 SD level), and PIVKA- II levels also more than reference range. Positive correlation was observed between PIVKA- II level and tumor size in 18 patients without vascular invasion. Accor ding t o HCC clinical staging, 10 patients (25.6%) belonged clinical stage Ⅱ. 5 pat ients (12.8%) Ⅲ, 24 pat ients ( 61.5%) Ⅳ. Both of PIVKA- II and sICAM- 1 levels of stage showed significantly higher than stage Ⅱ. PIVKA-Ⅱ showed more positive correlation with tumor size and clinical stage than sICAM- 1. No correlation was found between AFP and sICAM- 1, and positive correlation was AFP and PIVKA- II. Conclusion: In HCC patients with low AFP, sICAM- 1 and PIVKA- II correlated with tumor size and clinical stage. sICAM- 1 and PIVKA- II may be a useful marker of diagnosis . So, we need to further study to evaluate whether sICAM- 1 and PIVKA- II can be used as a marker of disease progression or prognosis . (Korean J Hepatol 1998;4:346 357)

KeyWords: Hepatocellular carcinoma (HCC), AFP, sICAM-1, PIVKA-II